Sanofi has agreed to acquire UK-based respiratory vaccine specialist Vicebio for $1.15 billion upfront plus up to $450 million in development and regulatory milestones. The acquisition brings Vicebio's molecular clamp vaccine technology and phase 1 bivalent vaccine candidate targeting RSV and human metapneumovirus (hMPV) into Sanofi's pipeline, complementing existing products and partnerships such as with Novavax. Sanofi aims to broaden its respiratory vaccine offerings beyond mRNA technology with this move, which is expected to close in Q4 2025.